Abstract
Protein kinase CK2 (formerly casein kinase II) is frequently upregulated in human cancers, and transgenic expression of CK2α in lymphocytes is oncogenic. Lymphomagenesis is dramatically acclerated by co-expression of a c-myctransgene, suggestive of a synergistic interaction between the kinase and the transcription factor. Since c-myccan be phosphorylated by CK2, we hypothesized that the synergy between CK2 and c-mycmight be due to a functional interaction of the two molecules. Pharmacologic inhibition of CK2 activity in cell lines established from CK2α transgenic T cell lymphomas reduces their proliferation and concomitantly with this, the steady state levels of c-mycprotein decline. This is caused by acclerated c-mycprotein turnover, which occurs in a proteasome-dependent manner. Transfection of cells with sense or anti-sense CK2 constructs modulates c-mycprotein levels in concert with the alteration in CK2 activity, validating the findings obtained using the kinase inhibitors. Thus, CK2 is a critical regulator of c-mycprotein stability and of the proliferation of these T cell lymphomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agullo G, Gamet-Payrastre L, Manenti S, Viala C, Remesy C, Chap H, Payrastre B . 1997 Biochem. Pharmacol. 53: 1649–1657
Allende JE, Allende CC . 1995 FASEB J. 9: 313–323
Bahram F, von der Lehr N, Cetinkaya C, Larsson LG . 2000 Blood 95: 2104–2110
Battistutta R, Sarno S, De Moliner E, Papinutto E, Zanotti G, Pinna LA . 2000 J. Biol. Chem. 275: 29618–29622
Bello-Fernandez C, Cleveland JL . 1992 Curr. Top. Microbiol. Immunol. 182: 445–452
Boldyreff B, Meggio F, Dobrowolska G, Pinna LA, Issinger OG . 1993 Biochim. Biophys. Acta 1173: 32–38
Bonvini P, Nguyen P, Trepel J, Neckers LM . 1998 Oncogene 16: 1131–1139
Bosc DG, Luscher B, Litchfield DW . 1999 Mol. Cell. Biochem. 191: 213–222
Bousset K, Henriksson M, Luscher-Firzlaff JM, Litchfield DW, Luscher B . 1993 Oncogene 8: 3211–3220
Bousset K, Oelgeschlager MH, Henriksson M, Schreek S, Burkhardt H, Litchfield DW, Luscher-Firzlaff JM, Luscher B . 1994 Cell. Mol. Biol. Res. 40: 501–511
Bush A, Mateyak M, Dugan K, Obaya A, Adachi S, Sedivy J, Cole M . 1998 Genes Dev. 12: 3797–3803
Critchfield JW, Butera ST, Folks TM . 1996 AIDS Res. Hum. Retroviruses 12: 39–46
Critchfield JW, Coligan JE, Folks TM, Butera ST . 1997 Proc. Natl. Acad. Sci. USA 94: 6110–6115
Davis AC, Wims M, Spotts GD, Hann SR, Bradley A . 1993 Genes Dev. 7: 671–682
Daya-Makin M, Sanghera JS, Mongentale TL, Lipp M, Parchomchuk J, Hogg JC, Pelech SL . 1994 Cancer Res. 54: 2262–2268
Dobrowolska G, Lozeman FJ, Li D, Krebs EG . 1999 Mol. Cell. Biochem. 191: 3–12
Dumont FJ, Staruch MJ, Fischer P, DaSilva C, Camacho R . 1998 J. Immunol. 160: 2579–2589
Erikson J, Nishikura K, ar-Rushdi A, Finan J, Emanuel B, Lenoir G, Nowell PC, Croce CM . 1983 Proc. Natl. Acad. Sci. USA 80: 7581–7585
Faust RA, Gapany M, Tristani P, Davis A, Adams GL, Ahmed K . 1996 Cancer Lett. 101: 31–35
Faust RA, Niehans G, Gapany M, Hoistad D, Knapp D, Cherwitz D, Davis A, Adams GL, Ahmed K . 1999 Int. J. Biochem. Cell Biol. 31: 941–949
Gapany M, Faust RA, Tawfic S, Davis A, Adams GL, Ahmed K . 1995 Mol. Med. 1: 659–666
Glover III CV . 1998 Prog. Nucleic Acids Res. Mol. Biol. 59: 95–133
Gregory MA, Hann SR . 2000 Mol. Cell Biol. 20: 2423–2435
Grosschedl R, Baltimore D . 1985 Cell 41: 885–897
Guerra B, Boldyreff B, Sarno S, Cesaro L, Issinger OG, Pinna LA . 1999 Pharmacol. Ther. 82: 303–313
Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM . 1988 J. Exp. Med. 167: 353–371
Henriksson M, Bakardjiev A, Klein G, Luscher B . 1993 Oncogene 8: 3199–3209
Kamei H, Koide T, Kojima T, Hashimoto Y, Hasegawa M . 1998 Cancer Biother. Radiopharm. 13: 185–188
Kelliher MA, Seldin DC, Leder P . 1996 EMBO J. 15: 5160–5166
Krebs EG, Eisenman RN, Kuenzel EA, Litchfield DW, Lozeman FJ, Luscher B, Sommercorn J . 1988 Cold Spring Harbor Symp. Quantit. Biol. 1: 77–84
Kuenzel EA, Krebs EG . 1985 Proc. Natl. Acad. Sci. USA 82: 737–741
Landesman-Bollag E, Channavajhala PL, Cardiff RD, Seldin DC . 1998 Oncogene 16: 2965–2974
Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, Seldin DC . 2001 Oncogene 20: 3247–3257
Lin JK, Chen YC, Huang YT, Lin-Shiau SY . 1997 J. Cell Biochem. 28–29: Suppl 39–48
Luscher B, Keunzel EA, Krebs EG, Eisenman RN . 1989 EMBO J. 8: 1111–1119
Munstermann U, Fritz G, Seitz G, Lu YP, Schneider HR, Issinger OG . 1990 Eur. J. Biochem. 189: 251–257
ole-MoiYoi OK, Sugimoto C, Conrand PA, Macklin MD . 1992 Biochemistry 31: 6193–6202
Penn LJ, Laufer EM, Land H . 1990 Semin. Cancer Biol. 1: 69–80
Pinna LA . 1994 Cell Mol. Biol. Res. 40: 383–390
Pinna LA, Meggio F . 1997 Prog. Cell Cycle Res. 3: 77–97
Ramsay G, Evan GI, Bishop JM . 1984 Proc. Natl. Acad. Sci. USA 81: 7742–7746
Reddy KB, Krueger JS, Kondapaka SB, Diglio CA . 1999 Int. J. Cancer 82: 268–273
Salghetti SE, Kim SY, Tansey WP . 1999 EMBO J. 18: 717–726
Schmidt EV, Pattengale PK, Weir L, Leder P . 1988 Proc. Natl. Acad. Sci. USA 85: 6047–6051
Seldin DC, Leder P . 1995 Science 267: 894–897
Snell V, Nurse P . 1994 EMBO J. 13: 2066–2074
Song DH, Sussman DJ, Seldin DC . 2000 J. Biol. Chem. 275: 23790–23797
Street AJ, Blackwood E, Luscher B, Eisenman RN . 1990 Curr. Top. Microbiol. Immunol. 166: 251–258
Trochon V, Blot E, Cymbalista F, Engelmann C, Tang RP, Thomaidis A, Vasse M, Soria J, Lu H, Soria C . 2000 Int. J. Cancer 85: 691–696
von Deimling A, Aguzzi A, Kleihues P, Land H, Wiestler OD . 1990 Verh. Dtsch. Ges. Pathol. 74: 432–436
Wang J, Xie LY, Allan S, Beach D, Hannon GJ . 1998 Genes Dev. 12: 1769–1774
Xu X, Toselli PA, Russell LD, Seldin DC . 1999 Nat. Genet. 23: 118–121
Yim H, Lee YH, Lee CH, Lee SK . 1999 Planta Med. 65: 9–13
Yin F, Giuliano AE, Van Herle AJ . 1999 Anticancer Res. 19: 4297–4303
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Channavajhala, P., Seldin, D. Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis. Oncogene 21, 5280–5288 (2002). https://doi.org/10.1038/sj.onc.1205640
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205640
Keywords
This article is cited by
-
Revisiting potential value of antitumor drugs in the treatment of COVID-19
Cell & Bioscience (2022)
-
CSNK2 in cancer: pathophysiology and translational applications
British Journal of Cancer (2022)
-
CIGB-300 anticancer peptide regulates the protein kinase CK2-dependent phosphoproteome
Molecular and Cellular Biochemistry (2020)
-
Distinct molecular pathways mediate Mycn and Myc-regulated miR-17-92 microRNA action in Feingold syndrome mouse models
Nature Communications (2018)
-
Re-evaluation of protein kinase CK2 pleiotropy: new insights provided by a phosphoproteomics analysis of CK2 knockout cells
Cellular and Molecular Life Sciences (2018)